menu
    • menu
    [{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Trypsinogen","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Cancer stem Cell","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"University of Jaen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ University of Jaen","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ University of Jaen"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Peter MacCallum Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Pancreatic Proenzyme","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Peter MacCallum Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Peter MacCallum Cancer Center"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Propanc Biopharma

    Menu

    Propanc Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trypsinogen,Chymotrypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Hosts Corporate Update Call on Recent Progress and Positive Results

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : PRP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : Trypsinogen,Chymotrypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trypsinogen,Chymotrypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Aust...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 15, 2023

                            Lead Product(s) : Trypsinogen,Chymotrypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pancreatic Proenzyme

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Peter MacCallum Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Propanc Biopharma Announces Strategic Pharma Partnering Initiative

                            Details : The partnership aims for Propanc's lead product candidate, PRP (pancreatic proenzyme), a mixture of two proenzymes, trypsinogen and chymotrypsinogen, advancing towards a Phase I, first-in-human study in advanced cancer patients.

                            Brand Name : PRP

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Pancreatic Proenzyme

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Peter MacCallum Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cance...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : PRP

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Pa...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.

                            Brand Name : PRP

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 16, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human St...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.

                            Brand Name : PRP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma’s CEO Comments On The 39 Granted Patents and 26 Patent Applications Under Examination in K...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : PRP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done i...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : PRP

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat...

                            Details : PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Brand Name : PRP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

                            Details : PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.

                            Brand Name : PRP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 18, 2022

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth